Tipharco Pharmaceutical Joint Stock Company (DTG) hereby provides an explanation to the State Securities Commission, the Hanoi Stock Exchange, and esteemed shareholders regarding the fluctuations in revenue and profit after tax in the Q2/2026 Financial Statements compared to 2025 as follows:
The Company's profit after tax for the second quarter of 2026 increased compared with the same period last year, mainly due to the Company's continued implementation of measures to enhance the efficiency of its production and business operations. In particular, raw material procurement was closely managed, contributing to the stabilization of raw material prices and, consequently, better control of production costs.
In addition, the Company adjusted its production and business plan in line with market demand, resulting in higher production output and more effective management of production costs, thereby improving the gross profit margin and increasing revenue during the period.
Furthermore, since the end of 2025, the Company has continued to closely manage its capital resources and debt structure. As a result, finance costs, primarily interest expenses, decreased compared with the same period last year, contributing to the improvement of the Company's business performance.
The above is the Company's explanation for the changes in its business results for the second quarter of 2026 compared with the same period last year. The Company respectfully provides this information to its shareholders, investors, and other relevant stakeholders.
Thank you for your attention./.
Attachments: